110683-66-4

Upstream product

• 109-65-9 1-bromo-butane 
• 496-14-0 1,3-dihydroisobenzofuran 
• 180068-03-5 n-butyl phthalan 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 89-95-2 2-methyl-benzyl alcohol 
• 75-03-6 ethyl iodide 
• 110683-65-3 ((E)-2-Pent-1-enyl)-benzoic acid methyl ester 
• 4122-56-9 methyl o-formylbenzoate 
• 693-25-4 n-pentylmagnesium bromide 
• 26311-42-2 2-n-pentylbenzoic acid 
• 26311-41-1 methyl o-amylbenzoate 
• 122654-40-4 4,4-Dimethyl-2-(2-pentyl-phenyl)-4,5-dihydro-oxazole 
• 100368-67-0 2-Amyl-benzamid 

Downstream Products

• 59059-43-7 2-n-pentylbenzaldehyde 
• 110698-31-2 (E)-3-(2-Pentyl-phenyl)-N-[3-(1H-tetrazol-5-yl)-2,3-dihydro-benzo[1,4]dioxin-5-yl]-acrylamide 
• 103178-04-7 2-Pentyl-N-[3-(1H-tetrazol-5-yl)-2,3-dihydro-benzo[1,4]dioxin-5-yl]-benzamide 
• 103175-75-3 4-Pentyl-N-[3-(1H-tetrazol-5-yl)-2,3-dihydro-benzo[1,4]dioxin-5-yl]-benzamide 
• 110683-35-7 o-amylcinnamic acid 
• 26311-42-2 2-n-pentylbenzoic acid 
• 151888-64-1 2-Diphenylacetyl-5-pentyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester 
• 1026260-46-7 2-Formylamino-2-(2-pentyl-benzyl)-malonic acid diethyl ester 
• 1026802-35-6 Methanesulfonic acid 2-pentyl-benzyl ester 

Relevant academic research and scientific papers

COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF

The present invention relates to new malodour-counteracting agents of formula (I) or stereoisomers thereof, particularly useful in blocking the olfactory perception of androstenone, Formula (I), wherein R1, R2, R3,R4, R5, R6, R7 and X have the same meaning as that defined in the claims. The present invention also relates to consumer products comprising said agents. The present invention also relates to the use of said agents to suppress or attenuate undesirable odour, as well as to methods to suppress or attenuate undesirable odour employing said compounds.

Process for producing cyclopropanecarboxylates

There is disclosed a process process for producing a cyclopropanecarboxylate of formula (1): 1which process comprises reacting cyclopropanecarboxylic acid of formula (2): 2with a monohydroxy compound of formula (3): R6OH??(3),in the presence of a catalyst compound comprising an element of to Group 4 of the Periodic Table of Elements.

Electron-transfer-induced reductive cleavage of phthalans: Reactivity and synthetic applications

The behavior of phthalan (1a) was investigated under conditions of electron transfer from alkali metals in aprotic solvents. Reaction with lithium in the presence of a catalytic amount of naphthalene in THF led to the reductive cleavage of an arylmethyl carbon-oxygen bond, with formation of a stable dilithium compound. Trapping of this intermediate with several electrophiles (alkyl halides, carbonyl derivatives, CO2) was successful. The extension of this procedure to several substituted phthalans (1b-i) was investigated, and the regiochemistry as well as the synthetic usefulness of these reactions are discussed.

Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents

STR1 Compounds of formula (I) in which the residues have the following meanings: a is (II) or (III); R1 is CH2 OH, CH3, CF3, COOR5 with R5 or, A is a trans, trans--CH=CH--CH=CH--or tetramet

A Novel Series of Selective, Non-Peptide Inhibitors of Angiotensin II Binding to the AT2 Site

The availability of peptide and non-peptide Ang II receptor antagonists has permitted the study of Ang II receptor heterogeneity.It is now widely recognized that there are at least two distinct Ang II receptor subtypes.AT1 receptors are selective in their recognition of agents such as losartan, DuP 532,L-158,809,SKF108566, and similar non-peptides.To date, all of the well-known actions of Ang II in mammals are blocked by the AT1 selective antagonists such as losartan and are thus designated as being mediated by the AT1 receptor.Although there have been reports of functional activity mediated through AT2 sites, the pharmacological role for the AT2 receptor has not yet been elucidated.Herein, we report the chemistry and SAR on a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids which have selective affinity for AT2 receptors.The most potent of which (19) has an IC50 of 30 nM for the AT2 receptor in the rat adrenal radioligand binding assay.

New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships

(p-Amylcinnamoyl)anthranilic acid (3a) had moderate antagonist activities against LTD4-induced smooth muscle contraction on guinea pig ileum and LTC4-induced bronchoconstriction in anesthetized guinea pigs. Modifications were made in the hydrophobic part (cinnamoyl moiety) and the hydrophilic part (anthranilate moiety) of 3a. A series of 8-(benzoylamino)-2-tetrazol-5-yl-1,4-benzodioxans and 8-(benzoylamino)-2-tetrazol-5-yl-4-oxo-4H-1-benzopyrans were revealed to be potent antagonists of leukotrienes C4 and D4. Among both series, ONO-RS-347 (18k) and ONO-RS411 (19h) were the most potent and orally active antagonists, respectively. Structure-activity relationships are discussed.